06:25 AM EDT, 09/17/2026 (MT Newswires) -- Elicera Therapeutics (ELIC.ST) received approval from the Swedish Medical Products Agency to launch the Carma clinical study's phase 2a trial of its B-cell lymphoma therapy ELC-301. The clinical-stage cell and gene therapy company said Thursday it will enroll six patients in the current dose-expansion phase. The initial phase of the trial, which covered a dose-escalation study with 12 patients, was completed with no dose-limiting toxicities reported.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.